Dako, a cancer diagnostic supplier based in Denmark, on Monday said it entered into a collaboration agreement with Amgen Inc. to develop a test for an experimental Amgen cancer drug.
The Thousand Oaks biotech giant and Dako, which is based Glostrup, will be attempting something difficult to achieve in drug development: the concurrent development of a drug and a genetic test for a specific cancer.
Dako Chief Executive Lars Holmkvist said the partnership furthers each company’s efforts in the emerging field of “personalized” medicine, in which a therapy is matched to a patient’s genetic make-up.
In a statement Holmkvist said, “the selection of patients most likely to benefit from a specific treatment will increase the probability of therapeutic success.”
Amgen shares on Friday closed down 1 percent to $67.78 on the Nasdaq. They are not trading Monday because of the Presidents’ Day holiday.